Apollomics Inc. · NASDAQ:APLM
Apollomics — SPAC Merger (September 2022)
27 slides from Apollomics's SPAC merger presentation, Sep 14, 2022
Slide 1: Investor presentation September 2022
Investor presentation September 2022
Slide 2: Important Information for Investors
Important Information for Investors This investor presentation (this “Presentation”) (references to which shall be deemed to include any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further enquiries) relates to a proposed busine
Slide 3: No Representations and Warranties
No Representations and Warranties No representation, warranty or undertaking, express or implied, is made or will be given by Apollomics, Maxpro and their respective affiliates and Representatives as to the fairness, accuracy, completeness or reliability of this Presentation and the information and
Slide 4: Transaction Highlights
Apollomics Inc. (“Apollomics”) and Maxpro Capital Acquisition Corp. ("JMAC") have entered into a definitive business combination agreement Transaction values Apollomics at $899M Transaction expected to close in the first quarter of 2023 100% rollover from legacy Apollomics shareholders $105.05M in t
Slide 5: Transaction Details: Sources, Uses and Pro Forma Capitalization
SOURCES ($M) USES ($M) PRO FORMA CAPITALIZATION (M Shares, %) Capitalization calculated on a net-exercise basis: 89.90M shares to Apollomics shareholders and vested option holders are net of exercise proceeds for pre-closing vested options; assumes $10 price per JMAC share; excludes JMAC public and
Slide 6: Apollomics: On a mission to discover ways to treat cancer
GlycoMimetics partnership for Uproleselan Series C ~$124M Series B $99M TYG partnership for Gastrin 17 ("G17") vaccine Edison Oncology partnership for pan-ErbB inhibitor Cancers c-MET VEGF/CSF1 R/b/cRAF pan-ERB CD40/ PD-L1 G17 vaccine PD-L1 E-selectin PD-1 OrbiMed ~$10M Series A 2016 2018 2020 2021
Slide 7: Maxpro Capital Acquisition Corp. Overview
Maxpro Capital Acquisition Corp. (Nasdaq: JMAC) is a publicly listed special purpose acquisition company that completed a $105.05M IPO on October 13, 2021 JMAC is sponsored by MP One Investment LLC, established by Maxpro Capital Ventures, a healthcare private equity fund Maxpro has deep insight and
Slide 8: Seasoned Executives at Apollomics
Sanjeev Redkar PhD, MBA President & Co-founder Guo-Liang Yu PhD Co-founder Chairman and CEO 28 years in oncology drug development 5 NDAs, 5 NCEs and 15 INDs/CTAs in previous roles Matrix Pharmaceuticals, SuperGen, Astex, Otsukaa Serial Entrepreneur Seasoned Executives at Apollomics Kin-Hung Peony Yu
Slide 9: Seasoned Executives at JMAC
Seasoned Executives at JMAC Moses Chen JMAC CEO Senior Executive Senior Executive Managing Director of Maxpro Ventures Ltd. since May 2018 20+ years of academic and biotech experience Rutgers, Caltech, VivoRx, AmCyte, Celgene, Meridigen, SyneuRx Consultant at KPMG in Taiwan since February 2021 Provi
Slide 10: Growth: From Discovery to Clinical towards Commercial
›Series A OrbiMed ›Phase 1 in US for APL-101 ›Phase 1 in Australia for APL- 501 ›Clinical team in US ›Series B and Series C ›APL-101: ›Phase 1 completed ›Global Phase 2 ›Registration path in US ›APL-106: ›Phase 1 initiated in China ›Phase 3 initiated in China ›APL-122, APL-102 FPI ›APL-101 (US-Globa
Slide 11: Our Pipeline
Our Pipeline Partner Trials Apollomics Trials Drug Candidate Target Category IP Rights Mono / Combo Indications Status Discovery Preclinical IND Phase 1 Phase 2 Phase 3 NDA Tumor Inhibitors APL-101 Vebreltinib c-Met Small molecule Global 1 Mono NSCLC, GBM, other solid tumors APL-122 ErbB1/2/4 Small
Slide 12: Vebreltinib (APL-101): ~$10B market opportunity in NSCLC with c-MET dysregulation
Exon-14 skip mutation (1L, 2L) c-Met amplifications, denovo c-Met amplifications, resistance driven ~ 6,300 patients* ~ 2,500 patients*** ~ 3,100 patients*** Epidermal Growth Factor Receptor (EGFR) mutated NSCLC population 1L EGFR+ in combination with osimertinib ~ 20,700 patients* $3B market opport
Slide 13: Approved c-MET inhibitors landscape
Agent* Manufacturer(s) MOA Line of Therapy* Biomarker (NGS) U.S. FDA Approval EU5 EMA Approval JP MHLW Approval CN NMPA Approval Patients with MET mutations Orpathys® (savolitinib) HutchMed and AstraZeneca (CN) MET inhibitor Relapsed / refractory or 1L, chemotherapy ineligible NSCLC w/ MET Ex14 skip
Slide 14: Vebreltinib: 3 Indications for near term NDA/sNDA submissions
Exon-14 skip mutated NSCLC c-Met amplifications in NSCLC c-Met fusions in GBM Highly specific c-Met inhibitor Brain penetration Safety data available from over 370 patients worldwide Orphan drug designation by FDA ~ 140 patients treated in Apollomics SPARTA trial ongoing in 13 countries and 90+ site
Slide 15: Activity in a Patient with Primary NSCLC Lesions and Brain Metastasis
Activity in a Patient with Primary NSCLC Lesions and Brain Metastasis Targeted Small Molecule TKI NSCLC with c-Met amplification Source: Yilong Wu et al, Presentation on Phase 1 Open Investigation of the Safety and Tolerability of Bozitinib Enteric Capsules in Late-Stage NSCLC with c-Met Amplificati
Slide 16: Activity in a Glioblastoma Patient with c-MET Amplification
Activity in a Glioblastoma Patient with c-MET Amplification On treatment for 2+Years 78-yr old female, GBM since May 2015, c-Met Amplification, target lesion Lt Subependymal Received 3 prior lines of therapies (Temodar 2015-2017, Avastin 2017-2018, Nivolumab 2018-2019) C1D1: 04Sep2019; 2+ yr treatme
Slide 17: Vebreltinib – Additional Indications
Vebreltinib – Additional Indications EGFR resistance & c-Met amplification Other solid tumors with c-Met alterations, beyond lung & brain Gastrointestinal cancers: colon, stomach, pancreatic, liver, cholangiocarcinoma Renal cell cancer Thyroid cancer Prostate cancer Breast cancer Ovarian, and other
Slide 18: Uproleselan (APL-106) seeks to address $1.4B market for AML
1L treatment naïve AML Relapsed refractory AML AML patients unfit for chemotherapy ~ 16,400 patients* ~ 12,600 patients* ~ 8,800, patients* $1.4B total AML market opportunity in China** Acute Myeloid Leukemia Uproleselan (APL-106) seeks to address $1.4B market for AML Source: *IQVIA Market Research;
Slide 19: Uproleselan (APL-106) First-In-Class E-Selectin Antagonist
Uproleselan (APL-106) First-In-Class E-Selectin Antagonist Enhances efficacy of chemotherapy & reduces mucositis (from chemotherapy) Protects normal HSCs through quiescence enhancement and ability for self-renewal Reduces chemotherapy-associated toxicity (e.g. severe mucositis) Disrupts cell adhesio
Slide 20: APL-106 Phase 3 Clinical trials in AML with near term readouts
1L treatment naïve AML Relapsed/ Refractory AML Multiple Myeloma (APL-108, next generation) Uproleselan (APL-106) AML- Phase 3 in China FDA & NMPA Breakthrough Therapy Designations FDA Fast Track Designation AML: Significant clinical unmet needs – high relapse rate, low survival rate Phase 1 /2 Effi
Slide 21: Uproleselan Efficacy and Safety Data from US Phase 2 Trial
Relapsed / Refractory AML N=47 Newly Diagnosed AML N=25 Response Data: CR/CRi Response Data: MRD Negative Rates 41% 72% 69% 56% Median Overall Survival (OS): 8.8 Months Median Event Free Survival (EFS): 9.2 Months Median Overall Survival (OS): 12.6 Months Survival Outcomes Enhanced Efficacy Improved
Slide 22: Uproleselan Global Clinical Programs in Acute Myeloid Leukemia
Uproleselan (APL-106) Global Clinical Programs in Acute Myeloid Leukemia Apollomics China Studies GlycoMimetics Global Studies GMI-Sponsored Global Phase 3 trial in r/r AML; FULLY ENROLLED NCI-Sponsored Trial in Newly Diagnosed AML “Fit” for Chemo; Target interim analysis 2022 UC Davis IST - Newly D
Slide 23: Pipeline of Early Clinical and Preclinical Programs
APL-801 APL-502 APL-501 APL-810 APL-122 APL-102 Phase 1 Potent MTKi against VEGFR1/2/3, b/cRAF, CSF1R, KIT, RET in Solid Tumors Phase 1 Brain penetrating pan-ErbB inhibitor for treatment-resistance in solid tumors IND filed in US by partner 1000-fold more potent E-selectin antagonist APL-108 Preclin
Slide 24: APL-122: Potent panERB Inhibitor
APL-122: Potent panERB Inhibitor Overcomes Treatment-Resistance In Solid Tumors & Crosses BBB to Address Brain Metastases APL-122 Effective In Treatment-resistant gastric cancer (HER2+) N87 xenograft APL-122 Effective In Treatment-resistant NSCLC (T790M+) H1975 xenograft Brain concentration plasma c
Slide 25: APL-102: Potent Multitargeted kinase inhibitor
APL-102: Potent Multitargeted kinase inhibitor against VEGFR1/2/3, b/cRAF, CSF1R, KIT, RET in Solid Tumors Unique kinase profile with inhibition of several other key immuno-oncogenic drivers Tumor regression in 52 PDX models, including gastric, colorectal, esophageal, and lung cancer HCC PDX model:
Slide 26: Near-term Catalysts
Near-term Catalysts 2024 2025 APL-102 and APL-122 Phase 1 readout Phase 2 advancement 2023 Anticipated closing of deSPAC transaction Complete Phase 1 Global AML Phase 3 readout APL-106 APL-101 Potential for US NDA submission for Exon 14 NSCLC Data readout of c-Met Amp+ NSCLC Data readout of Phase 2/
Slide 27: Additional Information
Additional Information These communications are being made in respect of the proposed transaction involving Apollomics Inc. (“Apollomics”) and Maxpro Capital Acquisition Corp. (“Maxpro”). These communications do not constitute offers to sell or the solicitations of offers to buy any securities or so